Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30178% above fair value
$26.41−0.22 (-0.83%)
Close on Nov 17, 2026Market cap $1.70BP/E –Yield –
Stoke Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Stoke Therapeutics's total assets was $393.97M at Jun 30, 2026. For fiscal 2025 it was $418.43M, up 54.1% from the year before. The highest annual figure on record is $418.43M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $418.43M | +54.1% |
| FY2024 | Dec 31, 2024 | $271.56M | +18.9% |
| FY2023 | Dec 31, 2023 | $228.34M | -10.8% |
| FY2022 | Dec 31, 2022 | $256.07M | +7.2% |
| FY2021 | Dec 31, 2021 | $238.87M | -19.8% |
| FY2020 | Dec 31, 2020 | $297.93M | +30.2% |
| FY2019 | Dec 31, 2019 | $228.75M | +112.7% |
| FY2018 | Dec 31, 2018 | $107.54M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $393.97M | +2.5% |
| Q1 FY2026 | Mar 31, 2026 | $443.28M | +8.9% |
| Q4 FY2025 | Dec 31, 2025 | $418.43M | +54.1% |
| Q3 FY2025 | Sep 30, 2025 | $360.26M | +22.8% |
| Q2 FY2025 | Jun 30, 2025 | $384.51M | +24.9% |
| Q1 FY2025 | Mar 31, 2025 | $406.89M | +98.3% |
| Q4 FY2024 | Dec 31, 2024 | $271.56M | +18.9% |
| Q3 FY2024 | Sep 30, 2024 | $293.32M | +22.3% |
| Q2 FY2024 | Jun 30, 2024 | $307.76M | +19.8% |
| Q1 FY2024 | Mar 31, 2024 | $205.18M | -27.2% |
| Q4 FY2023 | Dec 31, 2023 | $228.34M | -10.8% |
| Q3 FY2023 | Sep 30, 2023 | $239.89M | -13.6% |
| Q2 FY2023 | Jun 30, 2023 | $256.92M | -14.8% |
| Q1 FY2023 | Mar 31, 2023 | $281.80M | -10.8% |
| Q4 FY2022 | Dec 31, 2022 | $256.07M | +7.2% |
| Q3 FY2022 | Sep 30, 2022 | $277.63M | +9.4% |
| Q2 FY2022 | Jun 30, 2022 | $301.43M | +14.0% |
| Q1 FY2022 | Mar 31, 2022 | $315.94M | +13.3% |
| Q4 FY2021 | Dec 31, 2021 | $238.87M | -19.8% |
| Q3 FY2021 | Sep 30, 2021 | $253.77M | +26.9% |
| Q2 FY2021 | Jun 30, 2021 | $264.45M | +25.8% |
| Q1 FY2021 | Mar 31, 2021 | $278.91M | +26.3% |
| Q4 FY2020 | Dec 31, 2020 | $297.93M | +30.2% |
| Q3 FY2020 | Sep 30, 2020 | $199.94M | -16.3% |
| Q2 FY2020 | Jun 30, 2020 | $210.21M | -14.7% |
| Q1 FY2020 | Mar 31, 2020 | $220.84M | +105.4% |
| Q4 FY2019 | Dec 31, 2019 | $228.75M | – |
| Q3 FY2019 | Sep 30, 2019 | $238.83M | – |
| Q2 FY2019 | Jun 30, 2019 | $246.37M | – |
| Q4 FY2018 | Dec 31, 2018 | $107.54M | – |
See a number that looks wrong?